181 related articles for article (PubMed ID: 29200159)
21. Clinical features, outcomes and risk factors for posterior reversible encephalopathy syndrome in systemic lupus erythematosus: a case-control study.
Cui HW; Lei RY; Zhang SG; Han LS; Zhang BA
Lupus; 2019 Jul; 28(8):961-969. PubMed ID: 31208267
[TBL] [Abstract][Full Text] [Related]
22. Posterior Reversible Encephalopathy Syndrome: A Comparative Study of Pediatric Versus Adult Patients.
Habetz K; Ramakrishnaiah R; Raina SK; Fitzgerald RT; Hinduja A
Pediatr Neurol; 2016 Dec; 65():45-51. PubMed ID: 27720711
[TBL] [Abstract][Full Text] [Related]
23. Prognostic factors and seizure outcome in posterior reversible encephalopathy syndrome (PRES) in children with hematological malignancies and bone marrow failure: A retrospective monocentric study.
Danhofer P; Tomečková M; Černá D; Zapletalová D; Horák O; Aulická Š; Juříková L; Domanský J; Kovalčíková P; Pavlík T; Štěrba J; Ošlejšková H
Seizure; 2019 Nov; 72():1-10. PubMed ID: 31521834
[TBL] [Abstract][Full Text] [Related]
24. Anti-thrombin-III reduction and posterior reversible encephalopathy syndrome (PRES) in acute lymphoblastic leukaemia (ALL). New insight into PRES pathophysiology.
Piccin A; Dossi RC; Cassibba V; Stupnner S; Bonatti G; Cortelazzo S
Ann Hematol; 2012 Jul; 91(7):1153-5. PubMed ID: 22134830
[No Abstract] [Full Text] [Related]
25. Posterior reversible encephalopathy syndrome in cancer patients: a single institution retrospective study.
Kamiya-Matsuoka C; Paker AM; Chi L; Youssef A; Tummala S; Loghin ME
J Neurooncol; 2016 May; 128(1):75-84. PubMed ID: 26900076
[TBL] [Abstract][Full Text] [Related]
26. Posterior Reversible Encephalopathy Syndrome and Cerebral Sinus Thrombosis in a Case of Pediatric B-Cell ALL.
Fraint E; Miller R; Walter A
J Pediatr Hematol Oncol; 2017 Mar; 39(2):e71-e73. PubMed ID: 28060109
[TBL] [Abstract][Full Text] [Related]
27. Seizure outcomes of posterior reversible encephalopathy syndrome and correlations with electroencephalographic changes.
Sha Z; Moran BP; McKinney AM; Henry TR
Epilepsy Behav; 2015 Jul; 48():70-4. PubMed ID: 26071927
[TBL] [Abstract][Full Text] [Related]
28. Long-term risk of seizures and epilepsy in patients with posterior reversible encephalopathy syndrome.
Datar S; Singh T; Rabinstein AA; Fugate JE; Hocker S
Epilepsia; 2015 Apr; 56(4):564-8. PubMed ID: 25690439
[TBL] [Abstract][Full Text] [Related]
29. Epidemiology, Comorbidities, and Outcomes of Posterior Reversible Encephalopathy Syndrome in Children in the United States.
Thavamani A; Umapathi KK; Puliyel M; Super D; Allareddy V; Ghori A
Pediatr Neurol; 2020 Feb; 103():21-26. PubMed ID: 31481327
[TBL] [Abstract][Full Text] [Related]
30. Prognosis and treatment of seizures in children with acute lymphoblastic leukemia.
Maytal J; Grossman R; Yusuf FH; Shende AC; Karayalycin G; Lanzkowsky P; Schaul N; Eviatar L
Epilepsia; 1995 Aug; 36(8):831-6. PubMed ID: 7635103
[TBL] [Abstract][Full Text] [Related]
31. Does minimal central nervous system involvement in childhood acute lymphoblastic leukemia increase the risk for central nervous system toxicity?
Anastasopoulou S; Harila-Saari A; Als-Nielsen B; Eriksson MA; Heyman M; Johannsdottir IM; Marquart HV; Niinimäki R; Pronk CJ; Schmiegelow K; Vaitkeviciene G; Thastrup M; Ranta S
Pediatr Blood Cancer; 2022 Jul; 69(7):e29745. PubMed ID: 35488712
[TBL] [Abstract][Full Text] [Related]
32. Clinical features and outcomes of posterior reversible encephalopathy syndrome in patients with systemic lupus erythematosus.
Lai CC; Chen WS; Chang YS; Wang SH; Huang CJ; Guo WY; Yang WC; Huang DF
Arthritis Care Res (Hoboken); 2013 Nov; 65(11):1766-74. PubMed ID: 23687067
[TBL] [Abstract][Full Text] [Related]
33. Acute lymphoblastic leukemia in adolescents and young adults in Finland.
Usvasalo A; Räty R; Knuutila S; Vettenranta K; Harila-Saari A; Jantunen E; Kauppila M; Koistinen P; Parto K; Riikonen P; Salmi TT; Silvennoinen R; Elonen E; Saarinen-Pihkala UM
Haematologica; 2008 Aug; 93(8):1161-8. PubMed ID: 18556413
[TBL] [Abstract][Full Text] [Related]
34. Difficulty in Distinguishing Posterior Reversible Encephalopathy Syndrome, Hypoxic-Ischemic Insult, and Acute Toxic Leukoencephalopathy in Children.
Luckman J; Zahavi A; Efrati S; Gilad G; Snir M; Michowiz S; Goldenberg-Cohen N
Neuropediatrics; 2016 Jan; 47(1):33-8. PubMed ID: 26645328
[TBL] [Abstract][Full Text] [Related]
35. PRES in the course of hemato-oncological treatment in children.
Musioł K; Waz S; Boroń M; Kwiatek M; Machnikowska-Sokołowska M; Gruszczyńska K; Sobol-Milejska G
Childs Nerv Syst; 2018 Apr; 34(4):691-699. PubMed ID: 29198072
[TBL] [Abstract][Full Text] [Related]
36. Allogeneic bone marrow transplantation in first remission for children with very high-risk acute lymphoblastic leukemia: a retrospective case-control study in the Nordic countries. Nordic Society for Pediatric Hematology and Oncology (NOPHO).
Saarinen UM; Mellander L; Nysom K; Ringden O; Schroeder H; Glomstein A; Gustafsson G
Bone Marrow Transplant; 1996 Mar; 17(3):357-63. PubMed ID: 8704687
[TBL] [Abstract][Full Text] [Related]
37. Posterior reversible encephalopathy syndrome (PRES) during induction chemotherapy for acute myeloblastic leukemia (AML).
Battipaglia G; Avilia S; Morelli E; Caranci F; Perna F; Camera A
Ann Hematol; 2012 Aug; 91(8):1327-8. PubMed ID: 22237936
[No Abstract] [Full Text] [Related]
38. Neurological complications in childhood nephrotic syndrome: A systematic review.
Stabouli S; Chrysaidou K; Kupferman JC; Zafeiriou DI
Eur J Paediatr Neurol; 2019 May; 23(3):384-391. PubMed ID: 30837193
[TBL] [Abstract][Full Text] [Related]
39. Clinical predictors and differential diagnosis of posterior reversible encephalopathy syndrome.
Faille LD; Fieuws S; Van Paesschen W
Acta Neurol Belg; 2017 Jun; 117(2):469-475. PubMed ID: 28144796
[TBL] [Abstract][Full Text] [Related]
40. Predictors of seizures in patients with posterior reversible encephalopathy syndrome.
Hinduja A; Habetz K; Raina SK; Fitzgerald RT; Sahaya K
Epilepsy Behav; 2016 Aug; 61():97-101. PubMed ID: 27337161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
